Is Maravai Lifesciences Stock a Good Investment?
Maravai Lifesciences Investment Advice | MRVI |
- Examine Maravai Lifesciences' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Maravai Lifesciences' leadership team and their track record. Good management can help Maravai Lifesciences navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Life Sciences Tools & Services space and any emerging trends that could impact Maravai Lifesciences' business and its evolving consumer preferences.
- Compare Maravai Lifesciences' performance and market position to its competitors. Analyze how Maravai Lifesciences is positioned in terms of product offerings, innovation, and market share.
- Check if Maravai Lifesciences pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Maravai Lifesciences' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Maravai Lifesciences Holdings stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Maravai Lifesciences Holdings is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Maravai Lifesciences Stock
Researching Maravai Lifesciences' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 99.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.05. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Maravai Lifesciences recorded a loss per share of 1.04. The entity had not issued any dividends in recent years.
To determine if Maravai Lifesciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Maravai Lifesciences' research are outlined below:
| Maravai Lifesciences generated a negative expected return over the last 90 days | |
| Maravai Lifesciences has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 259.19 M. Net Loss for the year was (259.62 M) with profit before overhead, payroll, taxes, and interest of 108.31 M. | |
| Maravai Lifesciences has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Contact Levi Korsinsky by May 5, 2025 Deadline to Join Class Action Against Maravai ... |
Maravai Lifesciences Quarterly Good Will |
|
Maravai Lifesciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Maravai Lifesciences Holdings. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Maravai Lifesciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Maravai Lifesciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Maravai Lifesciences' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-07 | 2024-09-30 | -0.01 | -0.02 | -0.01 | 100 | ||
2024-05-08 | 2024-03-31 | -0.03 | -0.02 | 0.01 | 33 | ||
2023-05-08 | 2023-03-31 | 0.04 | 0.03 | -0.01 | 25 | ||
2025-02-20 | 2024-12-31 | -0.0401 | -0.06 | -0.0199 | 49 | ||
2024-02-22 | 2023-12-31 | -0.01 | 0.01 | 0.02 | 200 | ||
2023-11-07 | 2023-09-30 | 0.01 | -0.01 | -0.02 | 200 | ||
2021-03-02 | 2020-12-31 | 0.11 | 0.13 | 0.02 | 18 | ||
2022-11-02 | 2022-09-30 | 0.33 | 0.37 | 0.04 | 12 |
Maravai Lifesciences Target Price Consensus
Maravai target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Maravai Lifesciences' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 16 | Buy |
Most Maravai analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Maravai stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Maravai Lifesciences, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationMaravai Lifesciences Target Price Projection
Maravai Lifesciences' current and average target prices are 2.37 and 9.07, respectively. The current price of Maravai Lifesciences is the price at which Maravai Lifesciences Holdings is currently trading. On the other hand, Maravai Lifesciences' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Maravai Lifesciences Market Quote on 28th of March 2025
Target Price
Analyst Consensus On Maravai Lifesciences Target Price
Maravai Lifesciences Analyst Ratings
Maravai Lifesciences' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Maravai Lifesciences stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Maravai Lifesciences' financials, market performance, and future outlook by experienced professionals. Maravai Lifesciences' historical ratings below, therefore, can serve as a valuable tool for investors.Know Maravai Lifesciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Maravai Lifesciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Maravai Lifesciences Holdings backward and forwards among themselves. Maravai Lifesciences' institutional investor refers to the entity that pools money to purchase Maravai Lifesciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jennison Associates Llc | 2024-12-31 | 3 M | Geode Capital Management, Llc | 2024-12-31 | 2.8 M | State Street Corp | 2024-12-31 | 2.8 M | Marshall Wace Asset Management Ltd | 2024-12-31 | 2.8 M | Glenmede Trust Co Na | 2024-12-31 | 2.2 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 2.2 M | Bamco Inc | 2024-12-31 | 2.2 M | Fmr Inc | 2024-12-31 | 2.1 M | Ubs Group Ag | 2024-12-31 | 2 M | Gtcr Llc | 2024-12-31 | 20.2 M | Mackenzie Investments | 2024-12-31 | 12.4 M |
Maravai Lifesciences' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 597.69 M.Market Cap |
|
Maravai Lifesciences' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.22) | (0.21) | |
| Return On Capital Employed | (0.25) | (0.24) | |
| Return On Assets | (0.14) | (0.14) | |
| Return On Equity | (0.45) | (0.42) |
Determining Maravai Lifesciences' profitability involves analyzing its financial statements and using various financial metrics to determine if Maravai Lifesciences is a good buy. For example, gross profit margin measures Maravai Lifesciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Maravai Lifesciences' profitability and make more informed investment decisions.
Maravai Lifesciences' Earnings Breakdown by Geography
Basic technical analysis of Maravai Stock
As of the 28th of March, Maravai Lifesciences secures the Risk Adjusted Performance of (0.16), standard deviation of 5.52, and Mean Deviation of 3.83. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Maravai Lifesciences, as well as the relationship between them.Maravai Lifesciences' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Maravai Lifesciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Maravai Lifesciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Maravai Lifesciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Maravai Lifesciences' Outstanding Corporate Bonds
Maravai Lifesciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Maravai Lifesciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Maravai bonds can be classified according to their maturity, which is the date when Maravai Lifesciences Holdings has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MRFGBZ 395 29 JAN 31 Corp BondUS566007AC41 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Maravai Lifesciences' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Maravai Lifesciences' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.16) | |||
| Market Risk Adjusted Performance | (0.44) | |||
| Mean Deviation | 3.83 | |||
| Coefficient Of Variation | (501.41) | |||
| Standard Deviation | 5.52 | |||
| Variance | 30.47 | |||
| Information Ratio | (0.20) | |||
| Jensen Alpha | (1.05) | |||
| Total Risk Alpha | (0.94) | |||
| Treynor Ratio | (0.45) | |||
| Maximum Drawdown | 31.34 | |||
| Value At Risk | (7.91) | |||
| Potential Upside | 5.83 | |||
| Skewness | (1.24) | |||
| Kurtosis | 4.1 |
| Risk Adjusted Performance | (0.16) | |||
| Market Risk Adjusted Performance | (0.44) | |||
| Mean Deviation | 3.83 | |||
| Coefficient Of Variation | (501.41) | |||
| Standard Deviation | 5.52 | |||
| Variance | 30.47 | |||
| Information Ratio | (0.20) | |||
| Jensen Alpha | (1.05) | |||
| Total Risk Alpha | (0.94) | |||
| Treynor Ratio | (0.45) | |||
| Maximum Drawdown | 31.34 | |||
| Value At Risk | (7.91) | |||
| Potential Upside | 5.83 | |||
| Skewness | (1.24) | |||
| Kurtosis | 4.1 |
Consider Maravai Lifesciences' intraday indicators
Maravai Lifesciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Maravai Lifesciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Maravai Lifesciences Corporate Filings
8K | 20th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 19th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 4th of March 2025 Other Reports | ViewVerify | |
| 28th of January 2025 Other Reports | ViewVerify |
Maravai Stock media impact
Far too much social signal, news, headlines, and media speculation about Maravai Lifesciences that are available to investors today. That information is available publicly through Maravai media outlets and privately through word of mouth or via Maravai internal channels. However, regardless of the origin, that massive amount of Maravai data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Maravai Lifesciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Maravai Lifesciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Maravai Lifesciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Maravai Lifesciences alpha.
Maravai Lifesciences Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Maravai Lifesciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Maravai Lifesciences Historical Investor Sentiment
Investor biases related to Maravai Lifesciences' public news can be used to forecast risks associated with an investment in Maravai. The trend in average sentiment can be used to explain how an investor holding Maravai can time the market purely based on public headlines and social activities around Maravai Lifesciences Holdings. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Maravai Lifesciences' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Maravai Lifesciences and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Maravai Lifesciences news discussions. The higher the estimate score, the more favorable the investor's outlook on Maravai Lifesciences.
Maravai Lifesciences Corporate Management
| Kurt Oreshack | General VP | Profile | |
| Christine Dolan | Executive Technologies | Profile | |
| Brian Neel | Chief Production | Profile | |
| Peter Leddy | Executive Officer | Profile | |
| Christopher Benoit | Executive Enzymes | Profile | |
| Becky Buzzeo | Executive Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Maravai Lifesciences Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Maravai Lifesciences. If investors know Maravai will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Maravai Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.33) | Earnings Share (1.04) | Revenue Per Share | Quarterly Revenue Growth (0.24) | Return On Assets |
The market value of Maravai Lifesciences is measured differently than its book value, which is the value of Maravai that is recorded on the company's balance sheet. Investors also form their own opinion of Maravai Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Maravai Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Maravai Lifesciences' market value can be influenced by many factors that don't directly affect Maravai Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Maravai Lifesciences' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Maravai Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Maravai Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.